ResultsIQ

ResultsIQ › Latest results › 3B Blackbio Dx Limited

3B Blackbio Dx Limited Q2 FY27 results deck summary

NSE: 3BBLACKBIO · BSE: 532067

Results deck of 13 Nov 2026, summarised by AI from the filing.

3B BlackBio's H1 FY27 consolidated revenue from operations was ₹8,177.10 lakh, with MDx growth hoped at 15%–20% for FY 2026–27.

Key takeaways

  1. H1 revenue Consolidated revenue from operations ₹8,177.10 lakh (H1 2025-26: ₹5,613.67 lakh), including Coris sales of ₹1,780.23 lakh and a Coris EBITDA loss of ₹331 lakh.
  2. MDx guidance Management hopes MDx grows 15%–20% overall in FY 2026–27 across domestic and export sales, with geo-political tensions affecting sales as of now.
  3. Coris consolidation This is the first year with full H1 Coris numbers consolidated, versus consolidation only from 29 August 2025 last year.
  4. Export growth Exports rose to ₹657.49 lakh in Q2 FY27 from ₹497.85 lakh in Q2 FY26, with presence in 70+ countries and 200+ customers.
  5. Geopolitical risk Geo-political tensions are affecting sales, with some orders delayed or cancelled and logistics challenging.

Original filing on BSE

3B Blackbio Dx Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.